DE60307628D1 - Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen - Google Patents
Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufenInfo
- Publication number
- DE60307628D1 DE60307628D1 DE60307628T DE60307628T DE60307628D1 DE 60307628 D1 DE60307628 D1 DE 60307628D1 DE 60307628 T DE60307628 T DE 60307628T DE 60307628 T DE60307628 T DE 60307628T DE 60307628 D1 DE60307628 D1 DE 60307628D1
- Authority
- DE
- Germany
- Prior art keywords
- preparations
- inhibitors
- production
- xanthine phosphodiesterase
- phosphodiesterase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38447802P | 2002-05-31 | 2002-05-31 | |
US384478P | 2002-05-31 | ||
PCT/US2003/017042 WO2003101992A1 (en) | 2002-05-31 | 2003-05-30 | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60307628D1 true DE60307628D1 (de) | 2006-09-28 |
DE60307628T2 DE60307628T2 (de) | 2007-08-09 |
Family
ID=29712039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60307628T Expired - Lifetime DE60307628T2 (de) | 2002-05-31 | 2003-05-30 | Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen |
Country Status (17)
Country | Link |
---|---|
US (2) | US7074923B2 (de) |
EP (1) | EP1509525B9 (de) |
JP (1) | JP2005529934A (de) |
CN (2) | CN101538224A (de) |
AR (1) | AR040232A1 (de) |
AT (1) | ATE336494T1 (de) |
AU (1) | AU2003238822A1 (de) |
CA (1) | CA2483923A1 (de) |
CY (1) | CY1105774T1 (de) |
DE (1) | DE60307628T2 (de) |
DK (1) | DK1509525T5 (de) |
ES (1) | ES2270047T3 (de) |
HK (1) | HK1068139A1 (de) |
MX (1) | MXPA04011862A (de) |
PT (1) | PT1509525E (de) |
WO (1) | WO2003101992A1 (de) |
ZA (1) | ZA200408719B (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
EP1953162B9 (de) * | 2001-02-24 | 2012-10-31 | Boehringer Ingelheim Pharma GmbH & Co. KG | Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
EP1509524B1 (de) * | 2002-05-31 | 2008-03-26 | Schering Corporation | Xanthin-phosphodiesterase-v-hemmer polymorphe |
US7495004B2 (en) * | 2002-06-17 | 2009-02-24 | Glaxo Group Limited | Purine derivatives as liver X receptor agonists |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE602004006756T2 (de) * | 2003-07-31 | 2008-01-24 | Schering Corp. | Metabolite eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen |
PE20050985A1 (es) * | 2003-11-21 | 2005-11-26 | Schering Corp | Formulaciones de inhibidores de la fosfodiesterasa v |
DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004009039A1 (de) * | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
US7393847B2 (en) * | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7179809B2 (en) * | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
US7439370B2 (en) * | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
DE102004030502A1 (de) * | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
DE102004043944A1 (de) * | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004044221A1 (de) * | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
EP3542801A1 (de) * | 2007-08-17 | 2019-09-25 | Boehringer Ingelheim International GmbH | Purinderivate zur verwendung bei der behandlung von fap-bedingten erkrankungen |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
PE20110297A1 (es) * | 2008-08-15 | 2011-05-26 | Boehringer Ingelheim Int | Inhibidores de dpp-4 para la cicatrizacion de heridas |
KR20110067096A (ko) | 2008-09-10 | 2011-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
EP3366304B1 (de) | 2010-06-24 | 2020-05-13 | Boehringer Ingelheim International GmbH | Diabetestherapie |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
EP3468562A1 (de) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Kombinationen aus linagliptin und metformin |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903224B2 (en) * | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
JPH0372480A (ja) * | 1989-08-10 | 1991-03-27 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体及びそれらを有効成分とする気管支拡張剤 |
CA2030112A1 (en) | 1989-11-24 | 1991-05-25 | Yasuo Ito | Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same |
ZA914727B (en) * | 1990-06-21 | 1992-03-25 | Schering Corp | Polycyclic guanine derivatives |
JPH04128285A (ja) * | 1990-06-27 | 1992-04-28 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体 |
JPH04279586A (ja) * | 1991-03-05 | 1992-10-05 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体 |
JPH051065A (ja) * | 1991-06-20 | 1993-01-08 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体 |
ES2103918T3 (es) * | 1991-10-17 | 1997-10-01 | Ciba Geigy Ag | Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios. |
DE4411660A1 (de) * | 1994-04-05 | 1995-10-12 | Hoechst Ag | Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung |
DE19540798A1 (de) * | 1995-11-02 | 1997-05-07 | Hoechst Ag | Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel |
DK0812844T3 (da) * | 1996-06-07 | 2003-02-17 | Hoechst Ag | Anvendelse af theophyllinderivater til behandling og profylakse af choktilstande, nye xanthinforbindelser og fremgangsmåder til deres fremstilling |
HUP0301622A3 (en) * | 2000-07-04 | 2006-05-29 | Novo Nordisk As | Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
EP1953162B9 (de) * | 2001-02-24 | 2012-10-31 | Boehringer Ingelheim Pharma GmbH & Co. KG | Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
EP1421084B1 (de) | 2001-08-28 | 2008-05-14 | Schering Corporation | Polycyclische guanin phosphodiesterase inhibitoren |
JP2005509603A (ja) * | 2001-09-19 | 2005-04-14 | ノボ ノルディスク アクティーゼルスカブ | Dpp−iv酵素の阻害剤であるヘテロ環化合物 |
US6943171B2 (en) * | 2001-11-09 | 2005-09-13 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase V inhibitors |
WO2003057200A2 (en) * | 2002-01-11 | 2003-07-17 | Novo Nordisk A/S | Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
JP2004043429A (ja) * | 2002-02-25 | 2004-02-12 | Eisai Co Ltd | 新規キサンチン誘導体およびdppiv阻害剤 |
EP1509524B1 (de) * | 2002-05-31 | 2008-03-26 | Schering Corporation | Xanthin-phosphodiesterase-v-hemmer polymorphe |
US7495004B2 (en) * | 2002-06-17 | 2009-02-24 | Glaxo Group Limited | Purine derivatives as liver X receptor agonists |
BR122012026540B8 (pt) * | 2002-08-21 | 2021-05-25 | Boehringer Ingelheim Pharma | 8-[3-amino-piperidin-1-il]-xantinas, seus sais farmacêuticamente aceitáveis, seu uso e seu processo de preparação, bem como medicamento e seu processo de preparação |
AU2003269850A1 (en) * | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
AU2003280680A1 (en) * | 2002-11-01 | 2004-06-18 | Sumitomo Pharmaceuticals Co., Ltd. | Xanthine compound |
WO2005009343A2 (en) * | 2003-06-06 | 2005-02-03 | Endacea, Inc. | A1 adenosine receptor antogonists |
DE602004006756T2 (de) * | 2003-07-31 | 2008-01-24 | Schering Corp. | Metabolite eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen |
DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
-
2003
- 2003-05-30 CN CNA2009101321189A patent/CN101538224A/zh active Pending
- 2003-05-30 MX MXPA04011862A patent/MXPA04011862A/es active IP Right Grant
- 2003-05-30 DE DE60307628T patent/DE60307628T2/de not_active Expired - Lifetime
- 2003-05-30 CA CA002483923A patent/CA2483923A1/en not_active Abandoned
- 2003-05-30 US US10/449,526 patent/US7074923B2/en not_active Expired - Fee Related
- 2003-05-30 AT AT03734281T patent/ATE336494T1/de not_active IP Right Cessation
- 2003-05-30 AR ARP030101921A patent/AR040232A1/es unknown
- 2003-05-30 EP EP03734281A patent/EP1509525B9/de not_active Expired - Lifetime
- 2003-05-30 ES ES03734281T patent/ES2270047T3/es not_active Expired - Lifetime
- 2003-05-30 WO PCT/US2003/017042 patent/WO2003101992A1/en active IP Right Grant
- 2003-05-30 CN CNB038124971A patent/CN100497336C/zh not_active Expired - Fee Related
- 2003-05-30 JP JP2004509683A patent/JP2005529934A/ja active Pending
- 2003-05-30 PT PT03734281T patent/PT1509525E/pt unknown
- 2003-05-30 DK DK03734281T patent/DK1509525T5/da active
- 2003-05-30 AU AU2003238822A patent/AU2003238822A1/en not_active Abandoned
-
2004
- 2004-10-27 ZA ZA200408719A patent/ZA200408719B/en unknown
-
2005
- 2005-03-03 HK HK05101860A patent/HK1068139A1/xx not_active IP Right Cessation
-
2006
- 2006-05-08 US US11/429,719 patent/US7786301B2/en not_active Expired - Fee Related
- 2006-11-13 CY CY20061101635T patent/CY1105774T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1105774T1 (el) | 2011-02-02 |
MXPA04011862A (es) | 2005-03-31 |
US7786301B2 (en) | 2010-08-31 |
AU2003238822A1 (en) | 2003-12-19 |
US20030232987A1 (en) | 2003-12-18 |
US7074923B2 (en) | 2006-07-11 |
CN100497336C (zh) | 2009-06-10 |
CA2483923A1 (en) | 2003-12-11 |
CN101538224A (zh) | 2009-09-23 |
EP1509525B1 (de) | 2006-08-16 |
EP1509525A1 (de) | 2005-03-02 |
PT1509525E (pt) | 2006-12-29 |
ATE336494T1 (de) | 2006-09-15 |
AR040232A1 (es) | 2005-03-23 |
ZA200408719B (en) | 2005-11-15 |
CN1668618A (zh) | 2005-09-14 |
DE60307628T2 (de) | 2007-08-09 |
HK1068139A1 (en) | 2005-04-22 |
WO2003101992A1 (en) | 2003-12-11 |
JP2005529934A (ja) | 2005-10-06 |
DK1509525T3 (da) | 2006-12-11 |
DK1509525T5 (da) | 2007-07-30 |
EP1509525B9 (de) | 2007-10-31 |
US20060205943A1 (en) | 2006-09-14 |
ES2270047T3 (es) | 2007-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60307628D1 (de) | Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen | |
ATE556068T1 (de) | Verfahren zur herstellung substituierter pyrimidinde und pyrimidinderivate als inhibitoren von proteinkinasen | |
DE60210265D1 (de) | Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren | |
DE50213536D1 (de) | Xanthinderivate Verwendung als Arzneimittel sowie deren Verfahren zur deren Herstellung | |
DE60326628D1 (de) | Dorn und verfahren zur herstellung von stents | |
DE60301350D1 (de) | Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile | |
DE60324376D1 (de) | Halbleiterbauelement und Verfahren zu dessen Herstellung | |
DE60326012D1 (de) | Verfahren zur Konzentration von Proteinen | |
DE60303268D1 (de) | Verfahren und Vorrichtung zur Herstellung von Microarrays | |
DE60332463D1 (de) | Hochbrillianter mechanolumineszenzstoff und verfahren zu seiner herstellung | |
DE60329744D1 (de) | Aminosäurepulver und verfahren zu seiner herstellung | |
ATE505811T1 (de) | Verfahren zur nassbehandlung von scheibenförmigen gegenständen | |
DE60132637D1 (de) | Verfahren zur herstellung von pyrimidinonverbindungen und deren pharmazeutisch unbedenklichen salzen | |
DE50312128D1 (de) | Lenkung und Verfahren zur Lenkung | |
DE60215867D1 (de) | Verfahren zur herstellung von penamderivaten aus cephamderivaten | |
DE50300390D1 (de) | Verfahren zur Finishbearbeitung von Werkstücken | |
DE60128740D1 (de) | Verfahren zur Identifikation von im wesentlichen fehlerfreien Werkstücken | |
DE602004021388D1 (de) | Verfahren zur herstellung von cpla 2-inhibitoren | |
DE60234275D1 (de) | Verfahren zur herstellung von diglyceriden | |
DE60301283D1 (de) | Verfahren zur Bestimmung von Biopolymeren | |
DE60332964D1 (de) | Verfahren und vorrichtung zur temporären lagerung von linearen körpern | |
DE60315761D1 (de) | Verfahren zur Herstellung von Acylfluoriden | |
DE502004001633D1 (de) | Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten | |
DE60309524D1 (de) | Verfahren zur Ausrichtung und Verfahren zur Herstellung eines Artikels | |
DE50211253D1 (de) | Verfahren zur Herstellung von Makrokapseln |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |